[Clinical research on sequential dual-drug nonspecific immunotherapy in patients with hepatocellular carcinoma].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2018PMID: 29996346

View on PubMed DOI: 10.3760/cma.j.issn.1007-3418.2018.04.016

Plain Language Summary

This study investigated a sequential approach using two nonspecific immunotherapy agents in patients with hepatocellular carcinoma (liver cancer). The clinical research examined whether dual-drug immune stimulation could improve outcomes for liver cancer patients.

Authors

Zhou, J P; Yao, S Y; Chen, Y Y; Mo, Z J; Tang, Y T; Zhou, Y Q; Xu, C M; Liu, T Q

Keywords

Carcinoma, hepatocellularHepatectomyInterleukin-2Thymalfasinimmunotherapy